(Reuters) – The U.S. Food and Drug Administration (FDA) on Friday approved Bristol-Myers Squibb’s cell-based gene therapy, Breyanzi, to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or have relapsed after, at least two other types of systemic treatment. The FDA granted approval of Breyanzi for the treatment